Related posts

13 Recession-Proof Stocks for Portfolio SafetyFlat Wednesdaycash, credit and health
BUY
Abbott Labs

It's fallen so far and pays a good dividend. 

biotechnology / pharmaceutical
BUY
Abbott Labs

Medical devices, generics sold to EMs, nutrition. Lots of money during pandemic, money redeployed into new products. Attractive entry point. Yield is 2%, dividend increased every year.

biotechnology / pharmaceutical
TOP PICK
Abbott Labs

It is a diversified global health care company with four operating divisions.  Sales dropped dramatically after benefiting during Covid but the basic business is doing well with all divisions growing organically. Weight loss patients are using their drugs to monitor glucose. It has had 51 years of dividend increases.             Buy 19  Hold 7  Sell 0

(Analysts’ price target is $116.88)
biotechnology / pharmaceutical
BUY
Abbott Labs

Has owned this many years. She likes healthcare because of aging demographics. They made a lot of cash during Covid and have used that cash for M&A and R&D. Pays a nice 2.5% dividend. Has an established track record of raising their dividend annually. Trades at a reasonable PE. Lags healthcare, but still likes ABT. 

biotechnology / pharmaceutical
BUY
Abbott Labs

They beat their quarter due to their medical devices business

biotechnology / pharmaceutical
TOP PICK
Abbott Labs

It is a diversified medical device company with a large diagnostic business. It has made several acquisitions giving it a very diversified platform and is executing well in the cardio-vascular and diabetes fields.     Buy 20  Hold 7  Sell 1

biotechnology / pharmaceutical
BUY
Abbott Labs

Great company with long history of being shareholder friendly.
Dividend paid for ~100 years.
Excellent management team.


biotechnology / pharmaceutical
TOP PICK
Abbott Labs

Defensive. Very strong growth platform. Diagnostic business is right-sizing now, but organic growth of other businesses is double digits. Valuation is a bit more expensive at 23x earnings, but free cashflow yield is about 4%. 

Instead of innovation, they tend to acquire and enhance, which has been a knock against them. Big wins in cardiac portfolio and FreeStyle Libre glucose monitoring. Businesses are right in the sweet spot. Yield is 1.83%.

(Analysts’ price target is $123.14)
biotechnology / pharmaceutical
BUY
Abbott Labs

Reported an amazing quarter today, but the headlines reported a ho-hum beat. Shares lagged but eventually finished $8 higher today.

biotechnology / pharmaceutical
PAST TOP PICK
Abbott Labs
(A Top Pick Mar 15/22, Down 15%)

They made the Covid testing kits which generated $20 billion in revenues, so shares got ahead of itself. The market has ignored any such companies since then, but these earnings will eventually work their way up again. ABT has given guidance ex-Covid tests, meaning double-digit organic growth. This is a long-time core holding. They're in medtech and medical procedures are ramping up (a tailwind). Pays a constant and long-growing dividend now around 2.5%. She likes healthcare as a play on the aging population.

biotechnology / pharmaceutical
PAST TOP PICK
Abbott Labs
(A Top Pick Dec 09/22, Down 8%)

Still owns shares in the company.
Believes healthcare a good defensive name.
Target price of $110 per share.
Good performance in the past for the portfolio.
Averaged 16% growth the past 5 years.
Good company for the long term investor.

biotechnology / pharmaceutical
BUY
Abbott Labs
An emerging market healthcare play.
biotechnology / pharmaceutical
TOP PICK
Abbott Labs
Believes healthcare will hold up well in recessionary periods Has averaged 16% returns the last 5 years. Consistent earnings growth and profit margins. Large business with diverse revenue model. Has increased dividend the past 50 years.
biotechnology / pharmaceutical
PAST TOP PICK
Abbott Labs
(A Top Pick Oct 13/21, Down 7%) They made Covid test kits and generated $15 billion. They also have medical devices, a division that is improving, and pharmaceuticals that sell generic drugs to emerging markets, and infant formulas, but that ran into troubles. She likes their diversity and has many drugs in the pipeline. It has raised its dividend in the past 50 years. Happy to hold it.
biotechnology / pharmaceutical
BUY
Abbott Labs
Allan Tong’s Discover Picks Abbott stocks trade at a 25.18x PE at a low 0.74 beta, and pays a 1.73% dividend. Its valuation is significantly lower than peers Stryker (36.4x) and Becton Dickinson (37.3x) while its profit margin scores much higher at 17.35% vs. 11.56% and 9.59% respectively. ROI is also comparably higher while Abbott stock’s 1.73% divvy is in-line with this sector (and safe at a 42.17% payout ratio). Back to earnings: Abbott stocks have beaten their last four quarters handily. Read Our 3 defensive healthcare stocks picks for our full analysis.
biotechnology / pharmaceutical
Showing 1 to 15 of 180 entries

Abbott Labs(ABT-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 9

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 9 stock analysts published opinions about ABT-N. 9 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

9 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2023-12-04, Abbott Labs (ABT-N) stock closed at a price of $105.19.